Enzon Pharmaceuticals Inc  

(Public, NASDAQ:ENZN)   Watch this stock  
Find more results for ENZN
1.09
+0.02 (1.87%)
Feb 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.04 - 1.09
52 week 0.80 - 1.83
Open 1.05
Vol / Avg. 0.00/174,783.00
Mkt cap 49.01M
P/E 1.70
Div/yield 0.10
EPS 0.64
Shares 44.14M
Beta 1.15
Inst. own 52%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 92.99% 52.62%
Operating margin 93.01% 52.65%
EBITD margin - 67.16%
Return on average assets 118.90% 17.54%
Return on average equity 124.65% 43.88%
Employees 1 -
CDP Score - -

Address

20 KINGSBRIDGE ROAD
PISCATAWAY, NJ 08854
United States - Map
+1-732-9804500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company is dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs. The Company receives royalty revenues on seven marketed products that utilize its Customized PEGylation Linker Technology (Customized Linker Technology) platform, namely PegIntron, Sylatron, Macugen, CIMZIA, OMONTYS, Oncaspar and Adagen. PEGINTRON is a PEG-enhanced version of Merckļæ½s alpha interferon product, INTRON A, which is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Sylatron is approved for the adjuvant treatment of melanoma. Macugen (pegaptanib sodium injection) is being marketed by Valeant and Pfizer for the treatment of neovascular (wet) age-related macular degeneration, an eye disease associated with aging that destroys central vision.

Officers and directors

Jonathan N. Christodoro Chairman of the Board
Age: 38
Bio & Compensation  - Reuters
George W. Hebard III Interim Principal Executive Officer and Chief Operating Officer
Age: 40
Bio & Compensation  - Reuters
Richard L. Feinstein Principal Financial Officer, Vice President - Finance
Age: 70
Bio & Compensation  - Reuters
Odysseas D. Kostas M.D. Director
Age: 39
Bio & Compensation  - Reuters
Jennifer I. McNealey Director
Age: 40
Bio & Compensation  - Reuters